Sydney Jennings

Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.

Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.

Your daily dose of the clinical news you may have missed.

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

Your daily dose of the clinical news you may have missed.

New phase 3b data suggest that a modified titration of donanemab reduces the risk of brain swelling and fluid accumulation at 24 weeks.

Your daily dose of the clinical news you may have missed.

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.

The company is advancing development of the intranasal epinephrine medication following positive phase 1 data.

Your daily dose of the clinical news you may have missed.

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

Your daily dose of the clinical news you may have missed.

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

A single 750 mg intravenous infusion of Lu AG09222 showed a 2-day difference in reducing monthly migraine day compared with placebo.

V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.